))
Project Spotlight ∣ H2O: Strengthening the Patient Voice in Health Care
Manage episode 354601336 series 2981180
コンテンツは eupatientsforum によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、eupatientsforum またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
In today’s episode, we will discuss the Innovative Medicines Initiative ‘H2O: Health Outcomes Observatory’ project.
The Health Outcomes Observatory (H2O) is a public-private partnership drawing together patients, providers, researchers, industry and policy makers who share an interest in putting patients at the heart of healthcare.
H2O is set to transform the use of patient-reported information in health care, enrich the interaction between patients and health care providers and, as a result, drive better outcomes for patients.
To help us understand more about H2O and the value of patient reported outcomes, we’ve invited two guests today; Linetta Koppert and Jolanda Koenders, the country leads for H2O in the Netherlands.
Linetta is surgical oncologist at Erasmus Medical Center in the Netherlands and is at the forefront of incorporating patient-reported outcomes into patient care. She works with patient-reported outcomes within the conversation room for breast cancer since 2015. Jolanda is head of new product planning at Takeda and is committed to increase patients’ access to innovative medicine through sustainable collaborations on the national and European level.
.
.
.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/
64 つのエピソード
シェア
